Free Trial

Q2 EPS Estimate for Denali Therapeutics Raised by Analyst

Denali Therapeutics logo with Medical background

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at Wedbush increased their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report issued on Wednesday, May 7th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.76) per share for the quarter, up from their previous forecast of ($0.77). Wedbush currently has a "Outperform" rating and a $30.00 price target on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Denali Therapeutics' FY2025 earnings at ($3.17) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.77) EPS and FY2028 earnings at ($1.10) EPS.

Several other equities analysts also recently commented on the company. Bank of America dropped their target price on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Morgan Stanley initiated coverage on Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 target price for the company. HC Wainwright reduced their price objective on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. William Blair raised Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $33.79.

Get Our Latest Stock Report on DNLI

Denali Therapeutics Price Performance

Shares of DNLI stock traded down $0.19 on Monday, hitting $13.97. 134,021 shares of the company's stock were exchanged, compared to its average volume of 1,091,593. The stock has a market cap of $2.03 billion, a P/E ratio of -5.05 and a beta of 1.49. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33. The company has a 50 day moving average of $14.13 and a 200 day moving average of $19.74.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period last year, the company posted ($0.68) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at $532,000. Proficio Capital Partners LLC purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at $514,000. JPMorgan Chase & Co. lifted its position in shares of Denali Therapeutics by 6.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock valued at $6,857,000 after buying an additional 14,324 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after buying an additional 149,939 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after buying an additional 843,996 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

(Get Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Read More

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines